Skip to Content

Treatment sequence should begin with Nivo+Ipi in patients with MM

Get the main clinical outcomes from the DREAMseq trial in this MEDtalk, presented by Medical Oncologist Michael B. Atkins. To determine what drugs to begin the treatment sequence in patients with RAFV600-mutant metastatic melanoma (MM), the trial compares the efficacy of the sequence of nivolumab/ipilimumab (Nivo/Ipi) followed by dabrafenib/trametinib (Dab/Tram) to the converse sequence.

Michael B. Atkins

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top